Pharmacophore definition and three-dimensional quantitative structure-activity relationship study on structurally diverse prostacyclin receptor agonists.

Prostacyclin is an endogenous mediator that shows potent platelet inhibitory activity and powerful relaxation of peripheral resistance vessels. Prostacyclin receptor agonists are valuable drugs in the treatment of various vascular diseases spanning primary pulmonary hypertension to Raynaud's syndrome. Although agonists from various structural classes were synthesized, a common pharmacophore was never defined. Therefore, an attempt was made to integrate the different agonists into a single model. A dataset of structurally diverse prostacyclin receptor agonists was tested for its affinity to the human platelet prostacyclin receptor. The dataset included prostanoid and nonprostanoid ligands comprising iloprost, cicaprost, and BMY45778. Extensive conformational analyses were performed for both classes of compounds because of the absence of rigid templates. The search and superimposition procedure yielded a pharmacophore that aligns the essential carboxylate group of the agonists as well as demonstrates that different functional groups in prostanoid and nonprostanoid agonists can be arranged in a uniform conformation. A three-dimensional quantitative structure-activity relationship study was performed using the programs GRID and GOLPE. This analysis yielded a cross-validated correlation coefficient of 0.77. With this model, it is possible to predict the affinity of untested compounds.

[1]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[2]  R. Stehle [56] Physical chemistry, stability, and handling of prostaglandins E2, F2α, D2, and I2: A critical summary , 1982 .

[3]  N. Meanwell,et al.  Nonprostanoid prostacyclin mimetics. 3. Structural variations of the diphenyl heterocycle moiety. , 1992, Journal of medicinal chemistry.

[4]  J. Macdermot,et al.  Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics , 1986, British journal of pharmacology.

[5]  H. Vorbrüggen,et al.  Synthesis of ciloprost (ZK 36 374): a chemically stable and biologically potent prostacyclin analog. , 1983, Advances in prostaglandin, thromboxane, and leukotriene research.

[6]  C. Lemmen,et al.  FLEXS: a method for fast flexible ligand superposition. , 1998, Journal of medicinal chemistry.

[7]  L. Audoly,et al.  Substitution of charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction of the prostaglandin EP3 receptor. , 1997, Molecular pharmacology.

[8]  P. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[9]  Hans-Dieter Höltje,et al.  Structure-based 3D-QSAR—merging the accuracy of structure-based alignments with the computational efficiency of ligand-based methods , 2000 .

[10]  Ah-lim Tsai,et al.  Conformation of receptor-associated PGI2: An investigation by molecular modeling , 1991, J. Comput. Aided Mol. Des..

[11]  Non-prostanoid prostacyclin mimetics. 6. Derivatives of 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid modified beta-to the oxazole ring. , 1994, Drug design and discovery.

[12]  Y. Sugimoto,et al.  Selective Coupling of Prostaglandin E Receptor EP3D to Gi and Gs through Interaction of α-Carboxylic Acid of Agonist and Arginine Residue of Seventh Transmembrane Domain (*) , 1995, The Journal of Biological Chemistry.

[13]  Thomas Lengauer,et al.  Time-efficient flexible superposition of medium-sized molecules , 1997, German Conference on Bioinformatics.

[14]  Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted alpha to the oxazole ring. , 1993, Journal of medicinal chemistry.

[15]  A. Ichikawa,et al.  Functional interaction of the carboxylic acid group of agonists and the arginine residue of the seventh transmembrane domain of prostaglandin E receptor EP3 subtype. , 1997, The Biochemical journal.

[16]  L. Audoly,et al.  A conserved threonine in the second extracellular loop of the human EP2 and EP4 receptors is required for ligand binding. , 1998, European journal of pharmacology.

[17]  M Pastor,et al.  Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. , 1997, Journal of medicinal chemistry.

[18]  J. Regan,et al.  A single amino-acid substitution in the EP2 prostaglandin receptor confers responsiveness to prostacyclin analogs. , 1998, Molecular pharmacology.

[19]  N. Meanwell,et al.  Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic. , 1992, Journal of medicinal chemistry.

[20]  N. Meanwell,et al.  Non-prostanoid prostacyclin mimetics , 1994 .

[21]  N. Meanwell,et al.  Nonprostanoid prostacyclin mimetics. 2. 4,5-Diphenyloxazole derivatives. , 1992, Journal of medicinal chemistry.

[22]  N. Meanwell,et al.  Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid. , 1993, Journal of medicinal chemistry.

[23]  Robin Taylor,et al.  IsoStar: A library of information about nonbonded interactions , 1997, J. Comput. Aided Mol. Des..

[24]  P. Fuchs,et al.  Biochemical and pharmacological activity of arene-fused prostacyclin analogues on human platelets. , 1994, Prostaglandins.

[25]  Thomas Lengauer,et al.  RigFit: A new approach to superimposing ligand molecules , 1998, German Conference on Bioinformatics.

[26]  K. Schrör,et al.  The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia , 1993, European Journal of Clinical Pharmacology.

[27]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[28]  R. Armstrong Platelet prostanoid receptors. , 1996, Pharmacology & therapeutics.

[29]  H. Tai,et al.  Expression and site-directed mutagenesis of mouse prostaglandin E2 receptor EP3 subtype in insect cells. , 1995, The Biochemical journal.